{
    "address": "Vastertorpsvagen 135",
    "city": "Hagersten",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W4R93Q199",
    "description": "Intervacc AB engages in the development of novel veterinary vaccines. The company is headquartered in Hagersten, Stockholm and currently employs 12 full-time employees. The company went IPO on 2017-04-07. The company develops vaccines based on recombinant proteins for animal health care. The Company\u2019s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The firm operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. The company offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.",
    "employeeTotal": "12.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2017-04-07",
    "isin": "SE0009607252",
    "logo": "https://finnhub.io/api/logo?symbol=IVACC.ST",
    "marketCapitalization": 3897.462,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in Biotechnology",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Intervacc AB",
    "phone": "46812010600.0",
    "sedol": "BZBZVG1",
    "shareOutstanding": 50.160388,
    "state": "STOCKHOLM",
    "ticker": "IVACC.ST",
    "weburl": "http://intervacc.se/"
}